Durant J R
Semin Oncol. 1983 Dec;10(4 Suppl 4):29-33.
Progestins produce objective responses in about 30% of unselected patients with metastatic adenocarcinoma of the uterus. Selection of patients for treatment based on the presence of progesterone receptors may increase the probability of a response. There is little evidence to support a role of hormones as adjuvants in the primary management of poor-risk patients or in combination with chemotherapy. Antiestrogens may have a role as secondary agents in adenocarcinoma of the uterus, and progestins may have a role as secondary agents in ovarian cancer.
孕激素可使约30%未经挑选的子宫转移性腺癌患者产生客观反应。根据孕激素受体的存在来选择治疗患者可能会增加产生反应的概率。几乎没有证据支持激素在低风险患者的初始治疗中作为辅助药物或与化疗联合使用的作用。抗雌激素可能在子宫腺癌中作为二线药物发挥作用，而孕激素可能在卵巢癌中作为二线药物发挥作用。
